

## **IN THE CLAIMS**

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Claims 1-33 (canceled).

34. (previously presented) A composition comprising florfenicol butyrate and a pharmaceutically acceptable solvent selected from N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, triacetin, and combinations thereof, wherein the composition is formulated as a composition for administration to a mammal by injection.

35. (previously presented) The composition of claim 34, wherein the solvent is selected from propylene glycol, glycerol formal, and combinations thereof.

36. (currently amended) The composition of claim 35, wherein the pharmaceutically acceptable solvent carrier is a combination of propylene glycol and glycerol formal.

37. (previously presented) The composition of claim 34, wherein the concentration of florfenicol butyrate in the composition is at least about 200 mg/mL.

Claims 38-44 (canceled).

45. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 34.

46. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 35.

47. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 36.

48. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 37.

49. (canceled).

50. (New) The pharmaceutical composition of claim 34, wherein the solvent is selected from the group consisting of propylene glycol, glycerol formal, N-methyl pyrrolidone, and combinations thereof.

51 (New) The pharmaceutical composition of claim 50, wherein the solvent is a combination of propylene glycol, glycerol formal, and N-methyl pyrrolidone.

52. (New) The pharmaceutical composition of claim 50, wherein the solvent is a combination of propylene glycol and N-methyl pyrrolidone.

53. (New) The pharmaceutical composition of claim 50, wherein the solvent is a combination of glycerol formal and N-methyl pyrrolidone.

54. (New) The pharmaceutical composition of claim 34, wherein the solvent is selected from the group consisting of tetrahydrofurfuryl alcohol, N-methyl pyrrolidone, and combinations thereof.

55. (New) The pharmaceutical composition of claim 54, wherein the solvent is a combination of tetrahydrofurfuryl alcohol and N-methyl pyrrolidone.

56. (New) The pharmaceutical composition of claim 34, wherein the solvent is selected from the group consisting of propylene glycol, glycerol formal, N-methyl pyrrolidone, polyethylene glycol, and combinations thereof.

57. (New) The pharmaceutical composition of claim 56, wherein the solvent is a combination of polyethylene glycol and N-methyl pyrrolidone.

58. (New) The pharmaceutical composition of claim 56, wherein the solvent is a combination of polyethylene glycol and glycerol formal.

59. (New) The pharmaceutical composition of claim 56, wherein the solvent is a combination of polyethylene glycol and propylene glycol.

60. (New) The pharmaceutical composition of claim 56, wherein the solvent is a combination of polyethylene glycol, propylene glycol, and N-methyl pyrrolidone.